Which multiplex panels are used to detect Parkinson’s disease biomarkers in blood? Multiplexed blood biomarker panels for Parkinson’s disease are exemplifiedby advanced platforms like the NULISAseq™ Neuro 220 Panel,highlighted in Alamar Biosciences’ Parkinson’s Disease Grant Program. Thisapproach enables simultaneous measurementof 220+ protein biomarkers from a single blood sample, including 25 Parkinson’s disease–associated targets,providing a comprehensive view of disease biology. More Info : https://alamarbio.com/alamar-parkinsons-grant-program These multiplex panels are designed to capturekey pathways involved in Parkinson’s disease, such as protein aggregation (e.g., α-synuclein), neuroinflammation,lysosomal dysfunction (e.g., GBA1), and kinase signaling (e.g., LRRK2)—allowingresearchers to study disease mechanisms in a highly integrated manner. By leveraging ultra-sensitive NULISA™technology, these assays deliver highspecificity and attomolar-level sensitivity, enabling detection oflow-abundance biomarkers that are often undetectable with traditional methods. This multiplexed, high-throughput approachsupports biomarker discovery, patientstratification, early diagnosis, and therapeutic monitoring, making ita powerful solution for advancing Parkinson’s disease research and acceleratingprecision medicine initiatives.